WEBULL
WebtradeDownload

Can Zealand Pharma (CPSE:ZEAL) Justify Its Valuation On New Petrelintide Data?

Simply Wall St · 1d ago

Why the latest petrelintide data matters for Zealand Pharma stock

Zealand Pharma (CPSE:ZEAL) just reported positive topline Phase 2 ZUPREME-2 results for its amylin analog petrelintide in people with overweight or obesity and type 2 diabetes, giving investors fresh clinical data to assess.

Despite the fresh petrelintide data and recent events such as the Cambridge research hub opening and EASD presentations, Zealand Pharma’s share price has fallen 20.3% over the past month and 48.5% year to date, with a 1 year total shareholder return decline of 53.1%. This signals fading momentum despite ongoing clinical and pipeline progress.

Scan 124 healthcare AI stocks that could complement Zealand Pharma in obesity and metabolic care if you want more exposure to data driven breakthroughs in treatment and diagnostics.

After a drop of more than 50% over the past year, even as petrelintide moves into Phase 3, the key decision now is whether to buy Zealand Pharma at this reset level or wait for a potentially lower entry as expectations settle.

Most Popular Narrative: 43% Undervalued

With Zealand Pharma closing at DKK237 and the most followed narrative pointing to a fair value of DKK416, the current reset price sits well below what that framework assumes.

Substantial upcoming clinical catalysts, including Phase II (petrelintide) and Phase III (survodutide) data in obesity and obesity-related comorbidities, are expected within the next 12 to 18 months. Positive results could validate Zealand's differentiated pipeline and drive significant future revenue growth from milestone payments and royalties as therapies advance toward commercialization.

See why 27 investors see Zealand Pharma as 43% undervalued.

Result: Fair Value of DKK416 (UNDERVALUED)

Still, setbacks on key trials such as petrelintide, or tighter pricing and reimbursement for obesity drugs, could quickly erode confidence in the Zealand Pharma narrative.

Find out about the key risks to this Zealand Pharma narrative.

Next Steps

Mixed messages or a reset opportunity; either way, Zealand Pharma now has enough data and narrative debate for you to judge it on your own terms. Move quickly, weigh both sides of the story, and start with the 1 key reward and 2 important warning signs.

Looking for more investment ideas beyond Zealand Pharma?

If Zealand Pharma is only one piece of your portfolio puzzle, broaden your watchlist now so you do not miss other potential opportunities taking shape.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.